Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8506 to 8520 of 8902 results

  1. COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES23)

    This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.

    Withdrawn advice

  2. COVID-19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  3. COVID-19 rapid evidence summary: vitamin D for COVID-19 (ES28)

    This evidence summary has been updated and replaced by the COVID-19 rapid guideline on vitamin D (NG187).

    Withdrawn advice

  4. COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  5. COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  6. RapidAI for analysing CT/MRI brain scans in people with suspected acute stroke (MIB262)

    This advice has been updated and replaced by NICE healthtech guidance 708.

    Withdrawn advice

  7. Magtrace and Sentimag for locating sentinel lymph nodes (MIB263)

    This advice has been updated and replaced by NICE healthtech guidance 642.

    Withdrawn advice

  8. Alcohol: school-based interventions (PH7)

    This guideline has been updated and replaced by NICE guideline NG135.

    Withdrawn guideline

  9. Physical activity and the environment (PH8)

    This guideline has been updated and replaced by NICE guideline NG90.

    Withdrawn guideline

  10. Community engagement (PH9)

    This guidance has been updated and replaced by NICE guideline NG44.

    Withdrawn guideline

  11. Weight management: lifestyle services for overweight or obese adults (PH53)

    This guideline has been updated and replaced by NICE guideline NG246.

    Withdrawn guideline

  12. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

    Highly specialised technologies guidance
    Discontinued

  13. Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

    Discontinued Reference number: GID-HST10004

    Highly specialised technologies guidance
    Discontinued

  14. Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

    Discontinued Reference number: GID-DT9

    Diagnostics guidance
    Discontinued

  15. The Prosigna gene expression profiling assay for assessing long‑term risk of breast cancer recurrence (MIB27)

    This advice has been updated and replaced by NICE diagnostics guidance 34.

    Withdrawn advice